CMPS COMPASS Pathways Plc American Depository Shares
XNAS
11.05
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
CMPS
$11.05
—
Key stats
$11.05
Pre-market
$11.43
+3.44%
- 52-Week Range
- $4.88 – $15.87
- YTD
- +68.70%
- IV Rank (30D)
- 16.58
- Straddle Price
- $1.75
- P/C Vol Ratio
- 1.82
- Market Cap
- $1.5B
- Open
- $11.29
- Day Range
- $10.94 – $11.36
- Volume
- 1,520,359
- Prev Close
- $11.18
Fair Value
MODEL: NEUTRAL
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 1.37 |
| Cost of Equity (CAPM) | 12.50% (VRP-adj) |
| WACC | 12.39% |
| Volatility Risk Premium | +120.2pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.2B |
| Return on Equity (TTM) | -482.4% |
| Book / Price | 6.7% |
| Debt / Equity | 0.60 |
| Quality Score | 0/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $13.06 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $11.63 |
| Bollinger Width / SMA20 | 145.7% (drives anchor stability) |
| Net Debt | $-0.4B |
| Market Cap | $1B |
Peers used for multiples: ABBV, ANRO, ATAI, DFTX, HELP, NBIX, NRXP, RLMD
60-Day Conviction
17%
20-Day Fair Value
≈ by Nov 25, 2026
$11.05
α +0.0%
rank 41%
conviction
3%
40-Day Fair Value
≈ by Dec 24, 2026
$11.15
α +0.9%
rank 44%
conviction
31%
60-Day Fair Value
≈ by Jan 22, 2027
$11.10
α +0.5%
rank 40%
conviction
17%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | |
| Peer P/B | $2.93 | 31% | median 3.9× · 4 peers |
| Peer P/S | n/a | 0% | median 7.8× · 3 peers |
| Market Anchor (SMA50) | $13.06 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | $11.30 | 69% | 17 strikes · skew +0.22 |
As of 2026-10-27 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $1.5B
- Employees
- 156
- List Date
- 2020-09-18
- CIK
- 0001816590
- Next Earnings
- 2026-11-03 (Pre-Market)
- EPS Forecast
- ($0.42) (7 est.)
- Headquarters
- Chesire, X0
- Homepage
- https://compasspathways.com
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 0.53% | -31.64% | 34.46% | 25.36% | 3.86% | 2.14% | 5.79% |
| Feb | 6.16% | -12.33% | -22.24% | -9.44% | -8.82% | 4.39% | -7.05% |
| Mar | -26.15% | -11.83% | 22.14% | -27.53% | -22.07% | -21.23% | -14.45% |
| Apr | -3.23% | -32.24% | -18.99% | -11.47% | 42.65% | 61.21% | 6.32% |
| May | -4.14% | -7.24% | -9.16% | -12.97% | 1.46% | 44.95% | 2.15% |
| Jun | 10.71% | 27.59% | 9.09% | -20.53% | -35.93% | -0.28% | -1.56% |
| Jul | -4.57% | 44.35% | 9.78% | 28.24% | 37.66% | -15.64% | 16.64% |
| Aug | -0.12% | 9.37% | 1.12% | 8.72% | 1.84% | 20.09% | 6.84% |
| Sep | -10.19% | -33.35% | -20.69% | -12.80% | 26.77% | -6.04% | -9.38% |
| Oct | 36.57% | -1.86% | -16.59% | -20.13% | 9.53% | -7.53%* | -0.00% |
| Nov | -22.90% | -3.29% | 3.46% | -3.26% | -6.72% | -- | -6.54% |
| Dec | -30.94% | -21.43% | 43.44% | -15.81% | 31.68% | -- | 1.39% |
| Total | -49.62% | -66.75% | 11.73% | -60.16% | 63.63% | 72.26% | -4.82% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $11.63
SMA 50: $13.06
SMA 200: $10.31
Current: $11.05
EMA 12: $11.51
EMA 26: $12.02
MACD: -0.5065 | Signal: 0.0336
BEARISH
ADX (14): 24.53
WEAK TREND
+DI: 17.56
−DI: 29.30
Momentum Oscillators
RSI (14): 39.39
NEUTRAL
Stoch %K: 40.48
Stoch %D: 56.90
Williams %R: -76.43
Volume & Volatility
BB Upper: $12.61
BB Lower: $10.64
NEUTRAL
OBV: 85,098,412
Vol SMA 20: 2,600,276
Vol ROC: -22.49%
ATR: $0.63
True Range: $0.42
HV 20: 55.3%
HV 30: 59.0%
HV 60: 65.7%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
COMPASS PATHWAYS (CMPS) - COMPREHENSIVE STOCK ANALYSIS
Executive Summary
Overall Assessment: NEUTRAL with 6/10 Confidence
CMPS presents a conflicted technical and sentiment picture. While recent news headlines (April 17-27, 2026) strongly support a bullish narrative around Trump's psychedelic medicine executive order and sector momentum, the current technical setup shows deteriorating momentum and bearish positioning. The stock has already experienced a 40% spike on April 20, and current indicators suggest consolidation or pullback risk rather than sustained upside.
Key Drivers:
- Positive catalyst: Trump administration fast-tracking psychedelic treatments (April 20-27)
- Primary Risk: Post-spike consolidation; bearish technical divergence; high volatility environment
Investment Thesis: CMPS benefited from a significant tailwind in late April 2026 following regulatory tailwinds, but current technical deterioration (MACD bearish, RSI neutral-to-declining, volume down 49%) suggests the initial momentum may be exhausting. The 40% spike has likely attracted profit-taking, and the stock now requires confirmation above resistance at the $11.74 SMA 20 to sustain bullish momentum.
Recent News Sentiment Impact: Overwhelmingly positive (5 of 6 recent headlines positive), concentrated around April 17-27. The April 20 spike corresponds exactly with Trump executive order catalyst. However, this rally is now 7+ days old, and technical indicators have deteriorated—suggesting news impact has been priced in and momentum may be fading.
Technical Analysis
Trend Direction
Short-term (1-4 weeks): BEARISH
- Price at $11.18 is below the 20-day SMA ($11.74)
- EMA 12 ($11.59) above price, showing downward pressure
- MACD is deeply bearish: -0.50 below signal line (0.05), histogram -0.55
Medium-term (1-3 months): NEUTRAL-TO-BEARISH
- Price above 50-day SMA ($13.11)? NO—price is $1.93 below the 50-day, indicating medium-term downtrend prior to the April rally
- However, price is above 200-day SMA ($10.29), suggesting longer-term uptrend support
Long-term (3-12 months): BULLISH
- Price $0.89 above 200-day SMA ($10.29)
- $10.29 acting as key long-term support floor
Support & Resistance Levels
| Level | Type | Implication | |-------|------|-------------| | $12.91 | Resistance (BB Upper) | Recent spike high; breakout required | | $11.74 | Resistance (SMA 20) | Current rejection point; reclaim needed for short-term recovery | | $11.18 | Current Price | Weak midpoint; no clear support here | | $10.57 | Support (BB Lower) | First meaningful support | | $10.29 | Support (SMA 200) | Long-term support anchor; strong level | | $9.50-$10.00 | Support (Prior swing low) | Extended downside target if breakdown occurs |
Key Observation: The stock is sandwiched between SMA 20 resistance ($11.74) and Bollinger Band lower ($10.57). This 11% range represents a consolidation zone following the April 20 spike.
Momentum Signals
RSI (14): 40.43 — NEUTRAL, leaning bearish
- Not oversold (<30), but declining from higher levels
- Suggests momentum is waning but not yet capitulation
- Room to decline further before extreme oversold (<30)
MACD: -0.50 (Price) vs 0.05 (Signal Line) — BEARISH CROSSOVER
- Histogram deeply negative at -0.55 shows strong bearish momentum
- Price is below signal line—textbook bearish configuration
- This is the clearest bearish signal in the chart; suggests downside continuation risk
Stochastic Oscillators:
- %K (59.29) and %D (61.62) both in upper-middle range (40-80)
- Not yet overbought, but showing strength
- However, readings are declining from previous higher levels—momentum loss evident
Williams %R (-67.14): NEUTRAL-TO-BEARISH
- Readings between -80 (oversold) and -20 (overbought)
- At -67 suggests approaching oversold but not yet there
- Indicates potential bounce opportunity if support holds
Bollinger Bands:
- Price at $11.18 is near the middle band ($11.74)
- Width of 19.93% is moderate—not in squeeze (would be <10%) but not extreme expansion
- Signal: Neutral—band width suggests normal volatility, no breakout imminent
- No mean reversion play evident; price not at extremes
Volume Analysis
Volume Rate of Change: -49.25% — CRITICAL BEARISH SIGNAL
- Volume on recent trades is 49% below the 20-day average (2.6M shares)
- This sharp volume decline suggests institutional disinterest and weak conviction
- Post-spike rallies with declining volume typically fail and retrace
- Indicates the April 20 spike may have been driven by retail/retail options activity rather than sustained institutional accumulation
On-Balance Volume (OBV): 89M
- OBV remains positive, but trajectory matters more than absolute level
- Combined with volume decline, suggests OBV may be rolling over
- Indicates selling is beginning to outpace buying despite headline positivity
Interpretation: The 40% spike on April 20 was likely driven by short covering and retail enthusiasm following the Trump order. Current volume collapse suggests these buyers are now exiting, and there's insufficient buying pressure to sustain the rally.
News & Sentiment Analysis
Recent Headlines Summary
| Date | Headline | Theme | |------|----------|-------| | 2026-04-27 | Trump Executive Order Activates Psychedelics | Regulatory catalyst | | 2026-04-21 | Wall Street Betting on More Than Marijuana | Sector momentum | | 2026-04-20 | CMPS Rocketed 40% Today | Direct spike catalyst | | 2026-04-20 | Trump Fast-Tracked Psychedelic Treatments | Policy tailwind | | 2026-04-17 | Psychedelic Revolution in Mental Healthcare | Sector narrative | | 2026-02-26 | Psychedelic Medicine Advances: 5 Companies | General coverage |
Sentiment Assessment
Aggregate Sentiment: OVERWHELMINGLY POSITIVE (5 of 6 headlines positive)
- All recent headlines (April 17-27) center on Trump executive order fast-tracking psychedelic medicine approvals
- CMPS is specifically called out as "3 Under-the-Radar Stocks" and "Rocketed 40%"
- Sentiment is concentrated in a 10-day window (April 17-27), suggesting this is a momentum-driven narrative rather than fundamental shift
- No negative headlines in the recent batch; however, the lack of new headlines after April 27 is notable—suggests story may have already peaked media attention
Catalyst Identification
Immediate Catalysts (1-7 days):
- None identified; the Trump executive order catalyst has already been priced in (April 20 spike)
- Post-spike consolidation likely continues
Near-term Catalysts (1-4 weeks):
- Earnings on 2026-05-13 (approximately 2-3 weeks away)—CRITICAL
- This will be the first earnings test post-Trump catalyst
- Market may re-evaluate if earnings don't show early traction from regulatory tailwinds
- If Q1 2026 shows no improvement, the narrative could reverse sharply
- Regulatory updates on psychedelic trial approvals
Medium-term Catalysts (1-3 months):
- Next earnings on 2026-08-05
- FDA approval decisions on COMPASS's psilocysin programs
- Broader psychedelic sector momentum (or decline if sentiment shifts)
Market Narrative vs. Technical Signals
CRITICAL DIVERGENCE: News is bullish, but technicals are bearish
| Factor | Signal | Alignment | |--------|
Generated
News
All CMPS news →
Earnings History
15 of 16 under expected move
Avg Expected Move
22.05%
Avg Actual Move
6.55%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2022-02-24 | Pre-Market | 15.96% | 4.50% | 0.28x | Within |
| 2022-11-03 | Pre-Market | 15.31% | 4.80% | 0.31x | Within |
| 2023-02-28 | Pre-Market | 15.32% | 2.02% | 0.13x | Within |
| 2023-05-11 | Pre-Market | 14.90% | 0.81% | 0.05x | Within |
| 2023-08-03 | Pre-Market | 19.89% | 0.34% | 0.02x | Within |
| 2023-11-02 | Pre-Market | 17.82% | 2.94% | 0.16x | Within |
| 2024-02-29 | Pre-Market | 14.55% | 16.98% | 1.17x | Exceeded |
| 2024-05-08 | Pre-Market | 17.68% | 0.47% | 0.03x | Within |
| 2024-08-01 | After-Close | 17.81% | 2.33% | 0.13x | Within |
| 2024-10-31 | Pre-Market | 30.69% | 23.10% | 0.75x | Within |
| 2025-02-27 | Pre-Market | 41.89% | 5.95% | 0.14x | Within |
| 2025-05-08 | Pre-Market | 44.79% | 0.53% | 0.01x | Within |
| 2025-07-31 | Pre-Market | 36.80% | 10.41% | 0.28x | Within |
| 2025-11-04 | Pre-Market | 26.47% | 11.43% | 0.43x | Within |
| 2026-05-13 | After-Close | 6.61% | 3.10% | 0.47x | Within |
| 2026-08-05 | Pre-Market | 16.31% | 15.08% | 0.92x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
CMPS Options Activity & IV Rank
CMPS IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 77.2%
7-DTE IV: —
Expected Move: $1.75
7-DTE Move: $1.75
Days to Exp: 25 (2026-11-20)
Options Flow
Call Volume: 272
Put Volume: 496
P/C Volume: 1.824
BEARISH
Call OI: 21,669
Put OI: 19,835
P/C OI: 0.915
Total OI: 41,504
ATM Options Pricing
ATM Call: $0.97
ATM Put: $0.78
Call %: 8.8%
Put %: 7.0%
Chain Summary
Chain Volume: 9,652
Chain OI: 123,222
Last Updated: 10/26/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 35th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
35%
vs own history
GEX tilt
-0.01
OI-weighted, today
Vanna tilt
+0.84
δ-sensitivity to IV
Charm tilt
-0.86
δ-decay vs time
Vanna tilt +0.84: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.86: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 21 ATM contracts, 37k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · No data
30 DTE / 10d
0%
-4.2
pts
EXTREME
as of Oct 26 · ATM 76.1% / Wing 71.9%
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)16.6LowOct 26
Straddle Price (30 DTE)$1.75Oct 26
Beta Analysis
Risk Metrics
Beta: 1.5039
Alpha: 74.48%
Correlation: 0.2130
R-Squared: 4.5%
Stock Volatility: 90.0%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own CMPS
5 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Point72 Hedge fund Steve Cohen | $37.1M | #411 of 1945 | new | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $20.3M | #697 of 3138 | +65.5% | 13F | |
| Citadel Hedge fund Ken Griffin | $14.2M | #1349 of 6285 | +272.9% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $10.9M | #1516 of 3716 | -75.4% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $335K | #2296 of 4729 | +1753.0% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
CMPS Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 113,537,333 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
17 filers$86.90M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Caption Management, LLC | $27.54M | 31.70% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $26.86M | 30.90% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $7.57M | 8.71% | 2026-06-30 |
| 4 | Blue Owl Capital Holdings LP | $5.18M | 5.96% | 2026-06-30 |
| 5 | Simplex Trading, LLC Custodian | $4.89M | 5.63% | 2026-06-30 |
| 6 | Squadron Capital Management LLC | $4.32M | 4.97% | 2026-06-30 |
| 7 | Jane Street Group, LLC Custodian | $4.08M | 4.69% | 2026-06-30 |
| 8 | GROUP ONE TRADING LLC Custodian | $2.59M | 2.98% | 2026-06-30 |
| 9 | Creek Drive Management Group LLC | $1.70M | 1.95% | 2026-06-30 |
| 10 | PEAK6 LLC | $707.50K | 0.81% | 2026-06-30 |
| 11 | Goldman Sachs Group Inc Custodian | $584.39K | 0.67% | 2026-06-30 |
| 12 | Sender Co & Partners, Inc. | $318.38K | 0.37% | 2026-06-30 |
| 13 | Wolverine Trading, LLC Custodian | $305.83K | 0.35% | 2025-09-30 |
| 14 | Walleye Capital LLC | $232.06K | 0.27% | 2026-06-30 |
| 15 | SIGNATUREFD, LLC | $18.55K | 0.02% | 2026-09-30 |
| 16 | Walleye Trading LLC | $11.32K | 0.01% | 2026-06-30 |
| 17 | WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | $5.74K | <0.01% | 2026-09-30 |
9 filers$16.67M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $7.14M | 42.82% | 2026-06-30 |
| 2 | Caption Management, LLC | $2.95M | 17.69% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $2.70M | 16.17% | 2026-06-30 |
| 4 | GROUP ONE TRADING LLC Custodian | $1.29M | 7.71% | 2026-06-30 |
| 5 | DLD Asset Management, LP | $990.50K | 5.94% | 2026-06-30 |
| 6 | Jane Street Group, LLC Custodian | $915.50K | 5.49% | 2026-06-30 |
| 7 | Simplex Trading, LLC Custodian | $270.26K | 1.62% | 2026-06-30 |
| 8 | Wolverine Trading, LLC Custodian | $260.63K | 1.56% | 2025-09-30 |
| 9 | Walleye Capital LLC | $164.14K | 0.98% | 2026-06-30 |
CMPS Insider Trading (Form 4)
Latest: 2026-08-05Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-08-05 | Kabir Nath | Chief Executive Officer | Tax (F) | −5,962 | $11.25 | -$67.1K | EDGAR |
| 2026-05-29 | Gino Santini | Director | Grant (A) | +30,158 opt | — | EDGAR | |
| 2026-05-29 | Robert McQuade | Director | Grant (A) | +21,110 opt | — | EDGAR | |
| 2026-05-29 | David Y Norton | Director | Grant (A) | +21,110 opt | — | EDGAR | |
| 2026-05-29 | Wayne Joseph Riley | Director | Grant (A) | +21,110 opt | — | EDGAR | |
| 2026-05-29 | Daphne Karydas | Director | Grant (A) | +21,110 opt | — | EDGAR | |
| 2026-05-29 | Justin D. Gover | Director | Grant (A) | +21,110 opt | — | EDGAR | |
| 2026-05-29 | Jeffrey M Jonas | Director | Grant (A) | +21,110 opt | — | EDGAR | |
| 2026-05-29 | Kathleen Tregoning | Director | Grant (A) | +41,119 opt | — | EDGAR | |
| 2026-03-27 | Kabir Nath | Chief Executive Officer | Award (A) | +175,000 | — | EDGAR | |
| 2026-03-27 | Guy Goodwin | Chief Medical Officer | Grant (A) | +170,600 opt | — | EDGAR | |
| 2026-03-27 | Teri Loxam | Chief Financial Officer | Award (A) | +75,000 | — | EDGAR | |
| 2026-03-13 | Teri Loxam | Chief Financial Officer | Tax (F) | −1,781 | $6.89 | -$12.3K | EDGAR |
| 2026-03-13 | Kabir Nath | Chief Executive Officer | Tax (F) | −13,131 | $6.89 | -$90.5K | EDGAR |
| 2026-03-03 | Teri Loxam | Chief Financial Officer | Tax (F) | −4,467 | $7.02 | -$31.4K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
CMPS Insider Holdings
5 insiders · @ $11.05
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Kabir Nath | Chief Executive Officer | 361,028 | $3.99M | $0 | 13 | 2026-08-05 |
| 2 | Teri Loxam | Chief Financial Officer | 152,002 | $1.68M | $0 | 6 | 2026-03-27 |
| 3 | David Y Norton | Director | 20,356 | $224.9K | -$42.2K | 6 | 2026-05-29 |
| 4 | Annalisa Jenkins | Director | 19,480 | $215.3K | -$42.2K | 11 | 2025-06-13 |
| 5 | Guy Goodwin | Chief Medical Officer | 8,000 | $88.4K | $0 | 5 | 2026-03-27 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ETF Holders
13 ETFs hold CMPS
13 shown · $20.37M total exposure · 0.05% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.09% | $9.7M | $10.7B | 2026-10-23 |
| 2 | PSIL AdvisorShares Psychedelics ETF | Nport | 11.45% | $5.1M | — | 2026-06-30 |
| 3 | SURI Simplify Propel Opportunities ETF | Nport | 2.09% | $1.6M | — | 2026-06-30 |
| 4 | GWX State Street® SPDR® S&P® International Small Cap ETF | SPDR (State Street) | 0.12% | $1.1M | $896.9M | 2026-10-23 |
| 5 | AADR AdvisorShares Dorsey Wright ADR ETF | Nport | 2.09% | $873,055 | — | 2026-06-30 |
| 6 | HTEC ROBO Global Healthcare Technology and Innovation ETF | Nport | 0.93% | $639,663 | — | 2026-07-31 |
| 7 | ONEQ Fidelity Nasdaq Composite Index ETF | Fidelity | 0.00% | $525,974 | $10.7B | 2026-10-23 |
| 8 | BBC Virtus Biotech Clinical Trials Etf | Nport | 0.63% | $292,047 | — | 2026-07-31 |
| 9 | APIE ActivePassive International Equity ETF | Nport | 0.02% | $253,164 | — | 2026-08-31 |
| 10 | ISCF iShares International Small-Cap Equity Factor ETF | iShares (BlackRock) | 0.02% | $135,949 | $699.5M | 2026-10-23 |
| 11 | IBBQ Invesco Nasdaq Biotechnology ETF | Invesco | 0.10% | $115,143 | — | 2026-10-24 |
| 12 | BIB ProShares Ultra NASDAQ Biotechnology | ProShares | 0.06% | $59,095 | — | 2026-10-26 |
| 13 | ARKG ARK Genomic Revolution ETF | ARK Invest | 2.73% | — | — | 2026-10-26 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-4.61
TTM Revenue
—
TTM Net Income
$-407.75M
TTM Op. Cash Flow
$-161.14M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | — | $-253.79M | $-1.88 | $-40.31M |
| Q1 '26 | 2026-03-31 | — | $77.64M | $-0.30 | $-47.94M |
| Q4 '25 | 2025-12-31 | — | $-93.88M | $-0.99 | $-37.79M |
| Q3 '25 | 2025-09-30 | — | $-137.72M | $-1.44 | $-35.11M |
| Q2 '25 | 2025-06-30 | — | $-38.40M | $-0.41 | $-38.69M |
| Q1 '25 | 2025-03-31 | — | $-17.86M | $-0.24 | $-45.66M |
| Q4 '24 | 2024-12-31 | — | $-43.33M | $-0.63 | $-41.76M |
| Q3 '24 | 2024-09-30 | — | $-38.50M | $-0.56 | $-22.18M |
| Q2 '24 | 2024-06-30 | — | $-38.10M | $-0.56 | $-34.42M |
| Q1 '24 | 2024-03-31 | — | $-35.19M | $-0.55 | $-20.83M |
| Q4 '23 | 2023-12-31 | — | $-32.53M | $-0.51 | $-27.78M |
| Q3 '23 | 2023-09-30 | — | $-33.39M | $-0.67 | $-17.06M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-05
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
14.84
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-482.4%
ROA
-80.8%
Div Yield
0.00%
FCF Yield
-12.84%
Debt/Equity
0.60
Current Ratio
—
Market Cap
$1.25B
as of 2026-10-26
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
17.03M
SI % of Float
12.30%
Days to Cover
5.87
Short Vol Ratio
35.3%
Free Float
—
Float %
—
Short interest 2026-09-30 • Short volume 2026-10-26